

## STUDIES ON SERUM MAGNESIUM, PHOSPHOROUS AND CALCIUM IN CARDIOVASCULAR DISEASE PATIENTS ATTENDING HEART CLINIC AT ESUTH ENUGU

### ABSTRACT

This study was carried out to investigate the serum magnesium, phosphorous and calcium in cardiovascular disease patients attending heart clinic at ESUTH ENUGU. Blood samples were obtained by venipuncture from forty (40) patients consisting of ten (10) male cardiovascular disease patient (test subject) and ten (10) male non-cardiovascular disease patients (control subject), ten (10) female cardiovascular disease subject (test subject) and ten (10) female non-cardiovascular disease subject (control subject). Blood sample from each patient was analyzed for bone minerals (magnesium, phosphorous and calcium) by spectrophotometric method. Serum Ca was significantly lower ( $p=0.000$ ) in heart disease patients compared to Controls, while serum phosphorus was significantly higher ( $p=0.034$ ) in heart disease patients compared to Controls. There was no significant difference ( $p=0.493$ ) in serum Ca levels of heart disease patients compared to controls. Serum Ca was significantly negatively correlated with P in heart Disease Patients ( $r= -0.721$ ,  $p=0.000$ ). There was no significant correlation of serum Ca with Mg in heart Disease Patients ( $r= 0.074$ ,  $p=0.755$ ). Hyperphosphatemia and hypomagnesemia are risk factors for cardiovascular diseases.

## **1.0 INTRODUCTION**

Cardiovascular disease (CVD) is a key contributor to low quality of life and a leading cause of death worldwide [1, 2]. The Global Burden of Disease (GBD) Study 2019 revealed that since 1990, there has been a notable increase in the prevalence, mortality, and disability-adjusted life years (DALYs) associated with CVD [2]. It is well recognised that certain nutrients influence the onset and course of cardiovascular disorders. These include calcium, phosphorus, and magnesium. These micronutrients have historically been linked to chronic renal disease or bone health, but they may also raise the risk of cardiovascular disease (CVD) [3].

Elevated serum phosphorus levels are thought to increase CVD risk via vascular calcification [4], myocardial fibrosis [5], and the development of left ventricular hypertrophy [4]. High serum calcium levels may cause CVD and atherogenesis by increasing vascular calcification and coagulability [6, 7]. Serum calcium and phosphorus are required for bone mineralization, energy production, membrane transport, signal transduction, and vascular function [8]. Recent experimental and epidemiological studies have found that higher serum calcium or phosphorus levels may be associated with the pathogenesis of cardiovascular disease (CVD), including atherosclerosis [4, 9], heart valve calcification [10, 11], vascular calcification [4, 12], and arterial stiffness [13, 14]. In 2011, a meta-analysis of 47 cohort studies on this topic found that elevated blood phosphorus is strongly linked with higher all-cause and cardiovascular mortality [15]. There is limited evidence to establish a link between serum calcium and the risk of death and cardiovascular events in people with chronic kidney disease (CKD) [16]. Furthermore, recent evidence on the relationship between blood calcium and phosphorus and cardiovascular risk are debatable [17,18].

Another micronutrient that may be connected to the risk of CVD through a variety of physiologic functions is magnesium; low serum concentrations have been linked to abnormal ECG patterns, elevated blood pressure, chronic inflammation, impaired vasomotor tone and peripheral blood flow, and impaired glucose homeostasis and insulin action [19]. It has been suggested in more recent reports to be connected to the development of CVD [20, 21]. Magnesium, the second most prevalent intracellular cation and the fourth most abundant mineral, regulates cardiac contraction, intracellular conduction, and neuronal activation [22]. Moreover, magnesium is essential for controlling the activity of mitochondria and the synthesis of energy [23]. According to Liu et al. [24], mice on a low magnesium diet developed diastolic cardiomyopathy as a result of magnesium insufficiency due to ATP depletion, mitochondrial dysfunction, and reactive oxygen species overproduction. It has also been demonstrated that a shortage in magnesium causes endothelial dysfunction, platelet activation, and an increase in pro-inflammatory cytokines and neuropeptides, all of which speed up atherosclerosis [25]. A 22% lower incidence of heart failure was linked to an increase in magnesium intake through diet, according to a meta-analysis of prospective cohort studies [26]. Hospitalisation and the incidence of heart failure were linked to lower magnesium intake [27, 28].

Owing to these claims about the impact of micronutrients on the development of CVD, this study was aimed at evaluating the roles of calcium, phosphorus, and magnesium in the development of heart diseases. The aim was achieved by estimating and comparing the concentrations of calcium, phosphorus, and magnesium in individuals with heart disease and those without any history of heart disease.

## **2.0. METHODOLOGY**

### **2.1 Advocacy and mobilization and pre-survey contact**

Ethical approval was obtained from ethical/medical advisory committee of ESUTH Enugu after a proposal detailing the essence of the research was presented. Personnel anonymity was maintained, good laboratory practice was ensured, and all findings were treated with utmost confidentiality. All volunteers were verbally notified prior to sample collection and their informed consent was duly obtained.

### **2.3 Study design and population (subjects)**

This is a cross-sectional study. The study area is Enugu state, in the eastern region of Nigeria. The hospital attends to the medical needs of everyone living in the state. The period of subjects' enrolment, classification administration of questionnaires, sample collection, determination of heavy metals and data generation in this study lasted from November 2017 to January 2018. The subjects of the study were cardiovascular disease patients (both male and female subject with respect to age) at ESUTH Enugu. People without known cardiovascular disease were selected as control subjects. Random sampling was done across all age groups and the age was categorized as follows: 1-10, 11-20, 21-30, 31-40, 41- 50, 51-60 years. Furthermore, additional demographic data were obtained using questionnaires issued out during a structural interview. The demographic data include basic socioeconomic information, some medical health history and dietary intake of lead, arsenic cadmium, and mercury.

#### **2.4. Sample Collection and preparation.**

Fresh venous blood (5ml) was collected from the patients by venipuncture using a sterile needle and syringes into clean sterile and plain plastic tubes immediately. The unheamolysed samples in the tubes were centrifuged and separated. The serum samples were stored at -20°C prior to use.

#### **2.5 Estimation of Serum Calcium**

Serum calcium was determined by the colorimetric method of Leo [29]. The Randox reagent kit with catalog number CA590 was used. This assay is based on the principle that calcium ions form a violet complex with O-Cresolphthalein complexon in an alkaline medium. In this procedure, three clean grease-free test tubes were labeled- Test(T), Standard(S) and Blank(B). One milliliter (1ml) of calcium working reagent was added to each test tube. Into the test tube (T), 0.025ml of subject serum was added. Similarly, 0.025ml of calcium working standard was added into test tube S, and 0.02ml of distilled water was added into test tube B. Absorbance of the test was read at 570nm.

#### **2.6. Estimation of Serum Inorganic Phosphorous**

Serum calcium was determined by the colorimetric method by Leiboff [30]. The Teco Diagnostic reagent kit with catalog number 1515-480 was used for this assay. The principle is based on the reaction of inorganic phosphorous with ammonium molybdate in an acid medium to form a phosphomolybdate complex. This complex is reduced by ferrous ammonium sulfate to produce a molybdenum blue complex. The color produced is measured at 675nm and its intensity is directly proportional to the concentration of inorganic phosphorous present. The procedure involves the use of three clean grease-free test tubes were labeled- Test(T), Standard(S) and Blank(B). 1ml of phosphorous working reagent was added to each test tube and was incubated at room temperature. 0.02ml of subject serum was added in the test tube T. 0.02ml of phosphorous working standard was added into test tube S. 0.02ml of distilled water was added into test tube B. The test tubes were incubated for 10 minutes at 25°C. Absorbance of the test was read at 675nm.

#### **2.7. Estimation of serum Magnesium (Mg)**

Serum calcium was determined by the colorimetric method by Faulkner [31] and Tietz [32]. The reagent kit with catalog number M527-100, manufactured by Teco Diagnostic, was used for this study. The principle of the assay is that magnesium forms a colored complex with calmagite in alkaline medium to produce a red complex that is measured using spectrophotometer at 530nm. EGTA serves to complex and prevent calcium interference and a surfactant eliminates the effect of protein. The color produced is proportional to the magnesium concentration. The procedure involves the use of three clean grease-free test tubes were labeled- Test(T), Standard(S) and Blank(B). 1ml of magnesium working reagent was added to each test tube. 0.01ml of subject serum was added in the test tube T. 0.01ml of magnesium working standard was added into test tube S. 0.01ml of distilled water was added into test tube B. The test tubes were incubated for 5 minutes at room temperature. Absorbance of the test was read at 530nm.

#### **2.8 Statistical Analysis**

All values were expressed as mean  $\pm$  standard deviation, the test of significance was determined by student t-test. Values with  $P < 0.05$  were considered statistically significant.

### 3.0 RESULTS

#### 3.1: The concentrations of serum Ca, P and Mg in patients with heart disease and apparently healthy individuals

Serum Ca was significantly lower ( $p=0.000$ ) in heart disease patients compared to Controls, while serum phosphorus was significantly higher ( $p=0.034$ ) in heart disease patients compared to Controls. There was no significant difference ( $p=0.493$ ) in serum Ca levels of heart disease patients compared to controls (Table 1).

**Table 1: Serum Ca, P and Mg in Heart Disease Patients versus Controls**

VARIABLES (MEAN $\pm$ SD)	Heart Disease Patients (n=20)	Controls (n=20)	t-value	p-value
Mg(meq/L)	2.293 $\pm$ 1.65	2.60 $\pm$ 1.24	0.698	0.493
Lower 95% C.I	2.13	2.00		
Upper 95% C.I	3.73	3.19		
P(mg/dl)	3.31 $\pm$ 1.79	2.29 $\pm$ 0.70	2.285	0.034
Lower 95% C.I	2.46	1.96		
Upper 95% C.I	4.15	2.62		
Ca (mg/dl)	9.16 $\pm$ 1.52	11.02 $\pm$ 0.58	-4.850	0.000
Lower 95% C.I	8.47	10.75		
Upper 95% C.I	9.89	11.30		

#### 4.2: Pearson Correlation of Serum Ca with P and Mg in heart disease Patients

Serum Ca was significantly negatively correlated with P in heart Disease Patients ( $r= -0.721$ ,  $p=0.000$ ). There was no significant correlation of serum Ca with Mg in heart Disease Patients ( $r= 0.074$ ,  $p=0.755$ ) (Table 2).

**Table 2: Pearson Correlation of Serum Ca with P and Mg in Heart Disease Patients**

Dependent Variables	N	r-value	p-value
P	20	-0.721	0.000
Mg	20	0.074	0.755

### 4.0 DISCUSSION

This study was aimed at evaluating the concentrations of calcium, phosphorus, and magnesium (Mg) in cardiovascular disease patients. From the results, it was observed that the serum concentration of magnesium in cardiovascular disease patients was significantly lower than that of apparently healthy individuals (control group). This finding is in tandem with the report of Lutsey et al. [3], in which it was reported that low magnesium level increases the risk of cardiovascular diseases. It also agrees with the reports from some observational studies in which low serum magnesium was linked to more adverse CVD risk factor profiles [33, 34, 35] and greater risk of CVD events [36, 37, 38, 39, 40, 41]. Similarly, small randomized clinical trials of patients with heart failure have suggested that magnesium supplementation improves left ventricular function [42] and heart rate variability [43]. Furthermore, meta-analyses of community-based cohorts concluded that both a low Mg intake and low serum Mg level are significant risk for CVD events [20, 44, 45]. Therefore, it is most likely that magnesium might possess cardioprotective effects. That is to say, low serum level might predispose an individual

to cardiovascular diseases while a normal or slightly elevated level will protect or prevent an individual from developing cardiovascular diseases.

In this study too, it was found that serum calcium was significantly lower in heart disease patients compared to apparently healthy individuals (controls). This agrees with the report of Ranjan [46] in which he noted that serum calcium is lowered in cardiovascular diseases. Similar result was obtained in a study conducted by Lutsey et al. [3], in which Serum calcium was reported to be positively associated with the risk of incident heart failure. Furthermore, most observational studies of serum calcium concentrations have shown a positive association with the risk of myocardial infarction and combined CVD endpoints [47, 48, 49]. Therefore, it could be deduced that serum calcium level has an inverse relationship with cardiovascular diseases. That is to say, the risk of developing cardiovascular diseases increases with a decline in the serum calcium concentration.

On the other hand, it was observed in this study that serum phosphorus was significantly higher in heart disease patients compared to apparently healthy individuals. This agrees with the report in which higher phosphate levels were found to correlate with increased cardiovascular risk [50]. This also corroborates the findings of Lutsey et al. [3], in which serum phosphorus was positively associated with the risk of incident heart failure. Interestingly, several potential mechanisms by which phosphate leads to increased cardiovascular risk have been proposed [51]. It is documented that elevated phosphate levels induce degradation of the extracellular matrix and cause osteochondrogenic change in vascular smooth muscle cells [52]. These changes cause increased deposition of extracellular calcium phosphate crystals, cell apoptosis, and ultimately vascular calcification [53]. Furthermore, it has been proposed that hyperphosphatemia may also cause endothelial damage through increased production of reactive oxygen species [54, 55]. Also, Block et al. [56] reported a linear association of higher serum phosphate concentrations with a greater risk of cardiovascular hospitalizations in a national cohort of 40,538 hemodialysis patients. These all suggest that the elevated levels of phosphorus might increase the risk of developing cardiovascular diseases.

In this study, it was found out that serum calcium was significantly negatively correlated with phosphorus in cardiovascular disease patients. This implies that serum calcium decreases with increase in serum phosphorous in cardiovascular disease patients. This could be as a result of vascular calcification where calcium is deposited more in the bones with lower level found in serum in the presence of high serum level of phosphorous [57].

## **Conclusion**

There is growing evidence that increased concentration of phosphorus as well as decreased concentrations of calcium and magnesium levels enhances the development and progression of cardiovascular diseases. The findings from this study have further led credence to that body of knowledge. However, further research should be carried out in this area to better elucidate the mechanisms by which decreased or elevated levels of these micronutrients impact the cardiovascular health of individuals. Furthermore, the results from this study and similar results would aid in the proper diagnosis, treatment, and management of cardiovascular disease patients. In general, efforts should be made to ensure that these bone minerals (calcium, magnesium and phosphorous) are incorporated into daily diet to maintain their normal concentration in the body and reduce the risk of developing cardiovascular diseases.

## REFERENCES

1. Mensah GA, Roth GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. *J. Am. Coll. Cardiol.* 2019;74:2529–2532.
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *J. Am. Coll. Cardiol.* 2020;76:982–3021.
3. Lutsey PL, Alonso A, Michos ED, Loehr LR, Astor BC, Coresh J, Folsom AR. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. *The American Journal of Clinical Nutrition*, 100(3), 2014; 756–764.
4. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphate and left ventricular hypertrophy in young adults: the Coronary Artery Risk Development in Young Adults Study. *Kidney Blood Press Res* 2009;32:37–44.
5. Amann K, Tornig J, Kugel B, Gross M-L, Tyralla K, El-Shakmak A, Szabo A, Ritz E. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. *Kidney Int* 2003;63:1296–301.
6. Reid IR, Bolland M, Avenell A, Grey A. Cardiovascular effects of calcium supplementation. *Osteoporos Int* 2011;22:1649–58.
7. Reid IR, Bolland MJ. Calcium supplements: bad for the heart? *Heart* 2012;98:895–6.
8. Taylor JG, Bushinsky DA. Calcium and phosphorus homeostasis. *Blood Purif.* 2009;27:387–394.
9. Rubin MR, Rundek T, McMahon DJ, Lee HS, Sacco RL, Silverberg SJ. Carotid artery plaque thickness is associated with increased serum calcium levels: the Northern Manhattan study. *Atherosclerosis.* 2007;194:426–432.
10. Tarrass F, Benjelloun M, Zamd M, Medkouri G, Hachim K, Benghanem MG, Ramdani B. Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. *Nephrology (Carlton).* 2006;11:494–496.
11. Shuvy M, Abedat S, Beeri R, Danenberg HD, Planer D, Ben-Dov IZ, Meir K, Sosna J, Lotan C. Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. *Cardiovasc Res.* 2008; 79:492–499.
12. Shin S, Kim KJ, Chang HJ, Cho I, Kim YJ, Choi BW, Rhee Y, Lim SK, Yang WI, Shim CY, Ha JW, Jang Y, Chung N. Impact of serum calcium and phosphate on coronary atherosclerosis detected by cardiac computed tomography. *Eur Heart J.* 2012;33:2873–2881.
13. Sabanayagam C, Shankar A. Serum calcium levels and hypertension among U.S. adults. *J Clin Hypertens (Greenwich).* 2011;13:716–721.
14. Ix JH, De Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. *Clin J Am Soc Nephrol.* 2009;4:609–615.
15. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. *JAMA.* 2011;305:1119–1127.
16. Kwak SM, Jong SK, Choi Y, Chang Y, Kwon MJ, Jung JG, Jeong C, Ahn J, Hyun SK, Shin H, Ryu S. Dietary Intake of Calcium and Phosphorus and Serum Concentration in Relation to the Risk of Coronary Artery Calcification in Asymptomatic Adults. *Arteriosclerosis, Thrombosis, and Vascular Biology.* 2014;34(8):1763–1769.
17. Leifsson BG, Ahrén B. Serum calcium and survival in a large health screening program. *J Clin Endocrinol Metab.* 1996;81:2149–2153.
18. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. *Arch Intern Med* 2007;167:879–85. [

19. Rude RK. Magnesium. In: Coates PM, Betz JM, Blackman MR, Cragg GM, eds. *Encyclopedia of dietary supplements*. New York, NY: Informa Healthcare. 2010;527–37.
20. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K. Magnesium and the risk of cardiovascular events: A meta-analysis of prospective cohort studies. *PLoS ONE*. 2013;8:57720.
21. Rodríguez-Ortiz ME, Gómez-Delgado F, Arenas de Larriva AP, Canalejo A, Gómez-Luna P, Herencia C, López-Moreno J, Rodríguez M, López-Miranda J, Almadén Y. Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study). *Sci. Rep.* 2019;9:8013.
22. Tangvoraphonkchai K, Davenport A. Magnesium and Cardiovascular Disease. *Adv. Chronic Kidney Dis.* 2018;25:251–260.
23. Yamanaka R, Tabata S, Shindo Y, Hotta K, Suzuki K, Soga T, Oka K. Mitochondrial Mg<sup>(2+)</sup> homeostasis decides cellular energy metabolism and vulnerability to stress. *Sci. Rep.* 2016;6:30027.
24. Liu M, Liu H, Feng F, Xie A, Kang GJ, Zhao Y, Hou CR, Zhou X, Dudley SC. Magnesium Deficiency Causes a Reversible, Metabolic, Diastolic Cardiomyopathy. *J. Am. Heart Assoc.* 2021;10:020205.
25. Maier JA, Malpuech-Brugère C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: Implications for atherosclerosis, inflammation and thrombosis. *Biochim. Biophys. Acta.* 2004;1689:13–21.
26. Fang X, Wang K, Han D, He X, Wei J, Zhao L, Imam MU, Ping Z, Li Y, Xu Y, et al. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: A dose-response meta-analysis of prospective cohort studies. *BMC Med.* 2016;14:210.
27. Taveira TH, Ouellette D, Gulum A, Choudhary G, Eaton CB, Liu S, Wu WC. Relation of Magnesium Intake With Cardiac Function and Heart Failure Hospitalizations in Black Adults: The Jackson Heart Study. *Circ. Heart Fail.* 2016;9:002698.
28. Wu WC, Huang M, Taveira TH, Roberts MB, Martin LW, Wellenius GA, Johnson KC, Manson JE, Liu S, Eaton CB. Relationship between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI. *J. Am. Heart Assoc.* 2020;9:013570.
29. Leo GM. Direct Colorimetric Determination of Serum Calcium with o -Cresolphthalein Complexon. *American Journal of Clinical Pathology.* 1974; 61(1):114-117
30. Lieboff SL. A colorimetric method for determination of blood inorganic phosphorous. *Journal of Biological Chemistry.* 1928;79:611-619
31. Faulkner WR. Selected method for the small clinical chemistry laboratory. Magnesium in biological fluid. *AACC Washington, D.C.* 1982; pp. 277
32. Tietz NW. *Fundamentals of Clinical Chemistry.* W.B Saunders Co. Philadelphia. 1976; p.919.
33. Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. *Am J Hypertens.* 2002;15:691–6.
34. He K, Liu K, Daviglius ML, Morris SJ, Loria CM, Van Horn L, Jacobs DR, Savage PJ. Magnesium intake and incidence of metabolic syndrome among young adults. *Circulation.* 2006;113:1675–82.
35. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. *Diabetes Med.* 2006;23:1050–6.
36. Ohira T, Peacock JM, Iso H, Chambless LE, Rosamond WD, Folsom AR. Serum and dietary magnesium and risk of ischemic stroke. *Am J Epidemiol.* 2009;169:1437–44.
37. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J* 1998;136:480–90.
38. Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, Folsom AR. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J.* 2010;160:464–70.
39. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. *Mol Cell Biochem.* 2002;238:163–79.
40. Eisenberg MJ. Magnesium deficiency and sudden death. *Am Heart J* 1992;124:544–9.

41. Misialek JR, Lopez FL, Lutsey PL, Huxley RR, Peacock JM, Chen LY, Soliman EZ, Agarwal SK, Alonso A. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans; Atherosclerosis Risk in Communities (ARIC) Study. *Circ J*. 2013;77:323–9.
42. Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk H-D, Anker SD, Clark AL, Cleland JGF. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. *Eur Heart J*. 2005;26:2238–44.
43. Almoznino-Sarafian D, Sarafian G, Berman S, Shteinshnaider M, Tzur I, Cohen N, Gorelik O. Magnesium administration may improve heart rate variability in patients with heart failure. *Nutr Metab Cardiovasc Dis*. 2009;19:641–5.
44. Larsson SC, Orsini N, Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. *Am J Clin Nutr*. 2012;95:362–366.
45. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, et al. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. *Am J Clin Nutr*. 2013;98:160–173.
46. Ranjani G. Estimation of serum calcium and serum phosphorus levels in newly detected essential hypertensive patients. *International Archives of Integrated Medicine*. 2017;4(9):47-53
47. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J*. 2008;156:556–63.
48. Lind L, Skarfors E, Berglund L, Lithell H, Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. *J Clin Epidemiol*. 1997;50:967–73.
49. Jorde R, Sundsfjord J, Fitzgerald P, Bønaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromsø Study. *Hypertension*. 1999;34:484–90.
50. McGovern AP, De Lusignan S, Van Vlymen J, Liyanage H, Tomson CR, Gallagher H, et al. Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study. *PLoS ONE*. 2013;8(9):74996.
51. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. *Journal of the American Society of Nephrology*. 2008;19:1092–1105.
52. Lau WL, Pai A, Moe SM, Giachelli CM. Direct Effects of Phosphate on Vascular Cell Function. *Advanced Chronic Kidney Disease*. 2011;18: 105–112.
53. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, et al. Phosphate regulation of vascular smooth muscle cell calcification. *Circulation Research*. 2000;87: E10–17.
54. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. *Kidney international*. 2003;63: 1296–1301.
55. Chue CD, Townsend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. *Heart*. 2010;96: 817–823.
56. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in hemodialysis patients. *Journal of American Society of Nephrology*. 2004;15:2208–2218.
57. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation*. 2002;106:100-105.